Labiotech.eu’s Post

At the 3rd Annual TRP Summit, Kurt Hoeprich presented our innovative approach to n.c.a. Lu-177 production. He explained how our technology tackles supply chain challenges head-on. With our scalable production method, we're not just meeting current demand -- we're gearing up for the future of targeted cancer therapies. The event brought together experts from across the radiopharmaceutical field, sparking valuable discussions on the future of cancer treatment. Key insights from the summit: 🔎Lu-177 continues to dominate the radiopharmaceutical pipeline 🔎Tb-161 is emerging as a promising isotope 🔎Supply reliability remains a top priority in the industry We're committed to pushing innovation forward and improving outcomes for patients worldwide. #TargetedRadiotherapy #MedicalIsotopes #lutetium #terbium

BREAKING: Just hours before America's biggest cancer conference kicks off, a small biotech called Summit Therapeutics, Inc. made waves with new late-stage results. Summit's cancer drug beat Merck's flagship immunotherapy Keytruda in a Phase 3 lung cancer study conducted in China. That led to a multibillion-dollar stock move, with Summit gaining over $5 billion in market value on Thursday, while Merck's shares dropped just over 1%. It will also re-open contentious questions about the willingness of FDA regulators and US oncologists to rely on China-based clinical results. The success also boosts the chances of a rare repeat success in biotech for CEO Bob Duggan, who previously ran Pharmacyclics, an AbbVie Company, before selling it in 2015 for $21 billion and becoming a billionaire. My latest for Endpoints News:

As ESMO - European Society for Medical Oncology comes to a close, we are reflecting on all of the exciting developments we shared with everyone for EP0031 (A400/KL590586), a promising next generation selective RET inhibitor (SRI). Some key takeaways Elena Garralda Cabanas shared from our poster and presentation this weekend: - The poster presented at ESMO 2024 shows that EP0031 has an encouraging safety profile with evidence of efficacy in patients naïve to, or previously treated with 1st generation SRIs, and activity against brain metastases. - The in depth biomarker analysis presented supports the efficacy of EP0031 in patients that previously received a 1st gen SRI – independent of the presence of emergent RET resistance mutations. - Reductions in methylation-based tumour fractions and ctDNA appear to correlate with response to EP0031, with reductions in on-target RET resistance mutations also observed when present. The data highlights the early promise of these ctDNA-based methodologies as predictive biomarkers. - The Ellipses Phase 2 study continues to enrol patients in the US, UK and EU.   Read the poster in full: https://lnkd.in/ew8UmfBs #OncologyDrugDevelopment #EllipsesPharma #EP0031 #ESMO2024 #ClinicalTrials

We are thrilled having had Sebastian Lickert present our latest scientific results at the MarketsandMarkets Conferences in London ! #oncology #oncologyresearch #cancer #medicine #oncologia #immunooncology #healthcare #therapy #pharmaceutical #conference #marketsandmarkets 

In these two podcast episodes, GI oncologists use clinical cases of gastric and gastroesophageal (GE) cancer to demonstrate the application of treatment sequences, biomarker testing, and practice-changing data. In Episode 1, Dr. Samuel Klempner Dr. Elizabeth Smyth focus on a patient with non-metastatic cancer, while Episode 2 looks at a metastatic case, covering the latest developments in the field. Listen to both podcast episodes: https://lnkd.in/eR3XNAN4 Or listen on Spotify, Apple, or Google Podcasts. #MedEd #FreeMedEd #MedicalEducation #Oncology

Curious to learn more about Antibody-Drug Conjugates (ADCs)? Listen to the latest episode of the Biotech Matters Podcast by Bluestar BioAdvisors, LLC as my colleagues Erin Olsen and Jeff Fineberg discuss some of the lessons learned from approved ADCs and where we think things are headed. Do not hesitate to reach out with any questions! #biotech #pharma #oncology #cancer #ADC

🌟 Thrilling News! 🌟 Signet Therapeutics Inc., a portfolio company of BOCG, has received FDA IND approval for its groundbreaking targeted therapy for diffuse gastric cancer, moving into Phase I clinical trials. This therapy is the world's first to integrate organoid disease models with AI, developed in collaboration with XtalPi, showcasing rapid and efficient drug development. Beyond gastric cancer, this therapy shows promise in treating ovarian, triple-negative breast, and pancreatic cancers. BOCG is proud to support Signet Therapeutics' mission to bring effective therapies to patients worldwide. Read more here: https://lnkd.in/gGqr2YuG #BOCGPortfolio #BOCGFamily #Biotech #FDAApproval #ClinicalTrials #TargetedTherapy #BOCG #SignetTherapeutics #AI #Organoids #CancerResearch #Investment

A new report from PatientView delivers a powerful message to the pharma industry: patient-centricity is non-negotiable. This annual survey collects feedback from over 2,500 patient groups globally, highlighting that only 26% of these groups believe pharma is “Excellent” or “Good” at involving patient groups in R&D—a critical area for diseases like ALK+ lung cancer, where innovative treatments are urgently needed. The report emphasises the urgent need for pharmaceutical companies to intensify their focus on targeted treatments for unique subsets of patients. As patient groups seek greater involvement in research and development, a path we staunchly advocate for, it is clear the industry must adapt more inclusively. As pharma seeks to rebuild trust post-Covid, we must ensure that voices like ours are not just heard but are instrumental in shaping the therapies of tomorrow. #ALKPositive #LungCancerAwareness #PatientCentricity #PharmaNews

The development of monoclonal antibodies (mAbs) has paved the way for innovative treatments in oncology and autoimmune diseases. With the mAb therapeutic market expected to reach $300 billion by 2025, their role in transforming the therapeutic landscape is undeniable. In this whitepaper, we explore the latest progress in monoclonal antibody discovery & development and share insights into how automation can expedite the journey from bench to bedside. Download: https://becls.co/3LoybhZ #MonoclonalAntibodies #Automation #Whitepaper

The development of monoclonal antibodies (mAbs) has paved the way for innovative treatments in oncology and autoimmune diseases. With the mAb therapeutic market expected to reach $300 billion by 2025, their role in transforming the therapeutic landscape is undeniable. In this whitepaper, we explore the latest progress in monoclonal antibody discovery & development and share insights into how automation can expedite the journey from bench to bedside. Download: https://becls.co/3LoybhZ #MonoclonalAntibodies #Automation #Whitepaper